Beth Israel Medical Center

Beth Israel Medical Center was paid $278.66M by Medicaid between Jan 2018 and Dec 2024, across 757 billing codes. Its largest line is G2067, Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) — 16% of everything it billed.

Compared with peers

Next to other Psychiatric Hospital Unit providers in New York

Rank by total paid#1 of 33

Median peer was paid$171K

This provider vs. median1,632×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	25,893	$1.16M
2019	453,713	$21.39M
2020	1,000,226	$52.59M
2021	989,318	$53.68M
2022	800,687	$55.64M
2023	682,778	$56.28M
2024incomplete	450,496	$37.91M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)	16%	189,390	55,992	$43.44M
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	12%	989,059	105,151	$33.34M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	7.7%	186,326	158,191	$21.38M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	5.6%	136,927	120,503	$15.48M
G0396	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes	4.6%	118,700	66,747	$12.74M
90791	Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation	3.4%	10,389	8,753	$9.57M
J9271	Injection, pembrolizumab, 1 mg	3.4%	914	740	$9.50M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	2.9%	47,880	43,034	$8.05M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	1.8%	31,366	29,087	$5.15M
H0040	Assertive community treatment program, per diem	1.8%	2,758	2,728	$5.08M
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	1.5%	30,109	27,572	$4.22M
90834	Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient	1.5%	24,097	9,545	$4.12M

745 more codes

99285	Emergency room visit (most serious)	1.5%	27,220	$4.12M
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	1.2%	30,347	$3.40M
99204	Doctor's office visit, new patient (more involved)	1.2%	21,542	$3.35M
G0378	Hospital observation service, per hour	1.1%	3,114	$3.03M
36415	Collection of venous blood by venipuncture	1.0%	348,706	$2.82M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	44,190	$2.64M
G0397	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes	<1%	17,730	$2.52M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	39,944	$2.43M
96361	Intravenous infusion, hydration; each additional hour	<1%	12,135	$2.17M
99203	Doctor's office visit, new patient (routine)	<1%	14,755	$2.11M
J2426	Injection, paliperidone palmitate extended release (invega sustenna), 1 mg	<1%	987	$1.73M
J2505	Injection, pegfilgrastim, 6 mg	<1%	491	$1.73M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	9,428	$1.55M
H0004	Behavioral health counseling and therapy, per 15 minutes	<1%	29,551	$1.53M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	7,293	$1.52M
J0897	Injection, denosumab, 1 mg	<1%	1,051	$1.49M
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	7,042	$1.31M
G2078	Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	<1%	27,274	$1.24M
70450	Computed tomography, head or brain; without contrast material	<1%	6,940	$1.21M
H2001	Rehabilitation program, per 1/2 day	<1%	8,254	$1.19M
90853	Group psychotherapy (other than of a multiple-family group)	<1%	15,048	$1.16M
80053	Comprehensive metabolic panel	<1%	80,186	$1.12M
20611		<1%	7,137	$1.11M
78815	Positron emission tomography (PET) for limited area imaging	<1%	1,518	$1.07M
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	7,737	$1.02M
52000		<1%	1,196	$996K
97162		<1%	7,685	$977K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	5,681	$976K
H0005	Alcohol and/or drug services; group counseling by a clinician	<1%	13,218	$921K
96415		<1%	3,145	$896K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	19,294	$859K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	11,217	$857K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	38,405	$811K
90832	Psychotherapy session, about 30 minutes	<1%	5,718	$796K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	5,539	$775K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	344	$774K
80048	Basic metabolic panel (calcium, ionized)	<1%	52,188	$764K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	7,106	$750K
99205	Prolong outpt/office vis	<1%	4,119	$695K
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	179	$680K
87536		<1%	8,636	$669K
64615		<1%	1,098	$659K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	23,594	$622K
93970		<1%	2,350	$610K
93458		<1%	361	$594K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	3,096	$591K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	953	$582K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	2,282	$569K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	850	$528K
J2350	Injection, ocrelizumab, 1 mg	<1%	13	$519K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	2,014	$518K
31237		<1%	355	$510K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	18,059	$490K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	28,409	$474K
77336		<1%	1,887	$452K
77412		<1%	1,473	$437K
95004	Percutaneous tests with allergenic extracts, immediate type reaction	<1%	2,312	$437K
H0014	Alcohol and/or drug services; ambulatory detoxification	<1%	2,352	$427K
J3380	Injection, vedolizumab, intravenous, 1 mg	<1%	85	$417K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	3,128	$406K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	221	$403K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	4,123	$402K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	2,679	$401K
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	<1%	237	$396K
77386		<1%	1,069	$395K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	3,481	$394K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	2,571	$392K
51798		<1%	2,744	$382K
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	3,775	$379K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	17,671	$371K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	2,129	$366K
31231		<1%	4,229	$359K
99394	Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years)	<1%	3,419	$351K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	<1%	139	$344K
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	3,409	$342K
80061	Lipid panel	<1%	33,650	$321K
71250		<1%	4,461	$320K
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	4,969	$320K
76641		<1%	5,124	$315K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	459	$314K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	19,351	$307K
71275	Computed tomographic angiography, chest, with contrast material	<1%	1,679	$307K
H0002	Behavioral health screening to determine eligibility for admission to treatment program	<1%	1,441	$299K
93320		<1%	2,488	$298K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	18,001	$290K
96367		<1%	3,704	$288K
87428		<1%	10,932	$286K
10005		<1%	865	$284K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	1,265	$283K
99386		<1%	1,947	$274K
90792	Psychiatric diagnostic evaluation with medical services	<1%	1,293	$273K
86361		<1%	9,215	$271K
94375		<1%	2,103	$270K
70486		<1%	2,925	$263K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	8,806	$261K
99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	2,359	$261K
77063	Screening digital breast tomosynthesis, bilateral	<1%	10,884	$256K
93976		<1%	839	$256K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	19,377	$255K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	2,505	$255K
96375	Therapeutic injection; each additional sequential IV push	<1%	14,560	$254K
11900		<1%	1,144	$252K
99385		<1%	1,651	$246K
76536		<1%	3,231	$244K
86850		<1%	9,813	$242K
86480		<1%	4,165	$241K
76830	Ultrasound, transvaginal	<1%	3,956	$237K
76770		<1%	1,330	$235K
51741		<1%	1,402	$235K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	1,372	$233K
93880		<1%	1,277	$232K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	1,395	$229K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	853	$224K
93975		<1%	668	$214K
96910		<1%	2,275	$214K
70491		<1%	1,346	$210K
90460	Immunization administration through 18 years of age via any route, first or only component	<1%	10,891	$210K
70543		<1%	678	$208K
77066	Tomosynthesis, mammo	<1%	2,431	$208K
20610		<1%	738	$204K
J1453	Injection, fosaprepitant, 1 mg	<1%	1,966	$200K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	40,898	$199K
74183		<1%	744	$195K
46600		<1%	1,060	$194K
31575		<1%	1,985	$192K
G0382	Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	1,181	$191K
80076		<1%	22,678	$190K
S9485	Crisis intervention mental health services, per diem	<1%	163	$188K
77065	Tomosynthesis, mammo	<1%	2,942	$188K
17110		<1%	810	$187K
86901		<1%	10,026	$185K
86900		<1%	10,093	$182K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	1,148	$178K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	1,182	$175K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	1,487	$169K
71046	Radiologic examination, chest; 2 views	<1%	20,174	$169K
36000		<1%	9,449	$167K
73221		<1%	750	$166K
90677		<1%	1,363	$164K
83970		<1%	5,805	$164K
76998		<1%	1,056	$163K
90686		<1%	9,969	$162K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	50,128	$155K
86703		<1%	13,134	$155K
J9202	Goserelin acetate implant, per 3.6 mg	<1%	231	$148K
88307		<1%	1,056	$145K
93017		<1%	2,416	$144K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	14,230	$143K
76642		<1%	2,939	$142K
97165		<1%	1,310	$142K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	87,222	$142K
73564		<1%	6,886	$141K
83880		<1%	7,680	$141K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	2,767	$140K
97161		<1%	1,365	$140K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	1,685	$139K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	2,647	$137K
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	<1%	142	$135K
90750		<1%	1,134	$133K
94060		<1%	901	$130K
12011		<1%	372	$127K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	4,469	$121K
93971		<1%	1,911	$119K
90836		<1%	1,144	$116K
87507		<1%	786	$114K
99443		<1%	1,514	$113K
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	882	$113K
12001		<1%	356	$111K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,003	$110K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	188	$109K
93351		<1%	1,127	$109K
88342		<1%	2,132	$105K
93325		<1%	2,606	$104K
80050	General health panel	<1%	4,935	$102K
95800		<1%	889	$98K
96417		<1%	2,519	$98K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,373	$96K
10060		<1%	416	$95K
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	<1%	4,282	$95K
0002A		<1%	2,662	$95K
H0039	Assertive community treatment, face-to-face, per 15 minutes	<1%	57	$94K
72197		<1%	365	$93K
90461		<1%	3,545	$92K
H0033	Oral medication administration, direct observation	<1%	2,678	$92K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	1,191	$91K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	1,273	$90K
99051		<1%	8,755	$90K
77080		<1%	2,492	$89K
J0592	Injection, buprenorphine hydrochloride, 0.1 mg	<1%	6,206	$89K
83036	Hemoglobin; glycosylated (A1C)	<1%	30,073	$87K
77049		<1%	284	$87K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	268	$86K
69210		<1%	2,648	$85K
C1769	Guide wire	<1%	2,229	$84K
72141		<1%	515	$82K
90715		<1%	4,284	$80K
88185		<1%	1,055	$79K
90651		<1%	1,617	$79K
19083		<1%	67	$78K
0001A		<1%	2,684	$78K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	1,213	$76K
88112		<1%	1,588	$76K
95819		<1%	284	$75K
97803		<1%	2,417	$75K
J2315	Injection, naltrexone, depot form, 1 mg	<1%	66	$75K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	9,412	$72K
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	<1%	246	$72K
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	703	$71K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	153	$71K
70496		<1%	419	$71K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	148	$71K
87522	Neg quan hep c or qual rna	<1%	2,560	$71K
87631		<1%	1,686	$70K
52356		<1%	46	$70K
85610		<1%	24,203	$68K
70480		<1%	605	$67K
J2785	Injection, regadenoson, 0.1 mg	<1%	1,194	$66K
84443	Thyroid stimulating hormone (TSH)	<1%	20,401	$65K
73130		<1%	4,932	$64K
99442		<1%	1,127	$63K
11102		<1%	169	$63K
99201		<1%	514	$63K
96402		<1%	1,859	$63K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	<1%	31	$61K
83013		<1%	1,323	$60K
88304		<1%	2,672	$59K
77334		<1%	172	$59K
G0008	Administration of influenza virus vaccine	<1%	3,958	$58K
93356		<1%	591	$58K
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	285	$57K
95886		<1%	814	$56K
90732		<1%	604	$55K
90870		<1%	179	$55K
91200		<1%	1,336	$55K
90847	Family psychotherapy with the patient present, 50 minutes	<1%	225	$55K
73030		<1%	4,063	$55K
A9585	Injection, gadobutrol, 0.1 ml	<1%	4,150	$54K
88184		<1%	1,001	$54K
84439		<1%	13,111	$53K
77300		<1%	162	$52K
92557		<1%	1,393	$52K
86803		<1%	15,902	$50K
72125	Computed tomography, cervical spine; without contrast material	<1%	2,014	$50K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,577	$49K
59820		<1%	62	$49K
92551		<1%	1,123	$49K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	2,560	$49K
94726		<1%	791	$49K
90670		<1%	1,893	$48K
73562		<1%	3,313	$48K
76819	Fetal biophysical profile; without non-stress testing	<1%	1,150	$46K
74178		<1%	235	$46K
C1889	Implantable/insertable device, not otherwise classified	<1%	885	$46K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	1,210	$46K
73630		<1%	4,034	$45K
86003		<1%	3,399	$44K
J1944	Injection, aripiprazole lauroxil, (aristada), 1 mg	<1%	24	$44K
71271		<1%	574	$42K
87517		<1%	1,228	$41K
97016		<1%	2,473	$41K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,394	$39K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	15,839	$39K
92550		<1%	653	$38K
76801		<1%	707	$37K
87652		<1%	1,736	$35K
93225		<1%	290	$35K
90837	Psychotherapy session, about an hour	<1%	219	$34K
86769		<1%	1,133	$34K
87086	Culture, bacterial; quantitative colony count, urine	<1%	13,038	$33K
76818		<1%	694	$33K
82607		<1%	5,705	$32K
J9045	Injection, carboplatin, 50 mg	<1%	1,317	$32K
G0009	Administration of pneumococcal vaccine	<1%	2,112	$32K
92060		<1%	504	$32K
J9267	Injection, paclitaxel, 1 mg	<1%	1,223	$32K
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	6,917	$31K
81001		<1%	27,633	$31K
90734		<1%	1,560	$30K
72100		<1%	1,731	$30K
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	642	$30K
94729		<1%	813	$30K
82784		<1%	5,323	$29K
46607		<1%	49	$29K
82670		<1%	1,979	$29K
82728		<1%	5,956	$29K
76857		<1%	709	$28K
73610		<1%	2,763	$28K
J3490	Unclassified drugs	<1%	1,731	$28K
77062		<1%	689	$28K
84153		<1%	4,003	$28K
96401		<1%	604	$27K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	470	$27K
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)	<1%	2,649	$26K
95117		<1%	975	$26K
97163		<1%	174	$26K
96920		<1%	118	$26K
93925		<1%	174	$25K
93978		<1%	169	$25K
76937		<1%	195	$25K
73502		<1%	1,827	$25K
0004A		<1%	684	$25K
85730		<1%	17,311	$25K
87902		<1%	115	$25K
86780		<1%	8,938	$24K
99244	Office or other outpatient consultation, moderate to high complexity	<1%	147	$24K
85027		<1%	12,246	$24K
91320		<1%	318	$24K
88341		<1%	408	$24K
88172		<1%	542	$23K
0124A		<1%	628	$23K
87340		<1%	7,762	$22K
97116		<1%	785	$22K
77290		<1%	54	$22K
76775		<1%	488	$22K
96376		<1%	2,623	$22K
76813		<1%	459	$21K
86706		<1%	5,279	$21K
64483		<1%	39	$21K
95911		<1%	255	$21K
92567		<1%	485	$21K
83001		<1%	2,178	$21K
73110		<1%	1,997	$21K
84403		<1%	1,650	$21K
99243		<1%	143	$21K
T2022	Case management, per month	<1%	185	$20K
90648		<1%	1,750	$20K
J2704	Injection, propofol, 10 mg	<1%	8,945	$20K
83655		<1%	1,654	$20K
54161		<1%	19	$20K
74174		<1%	90	$19K
88173		<1%	694	$19K
86140		<1%	11,321	$19K
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	164	$19K
94010		<1%	682	$19K
J1631	Injection, haloperidol decanoate, per 50 mg	<1%	1,030	$18K
20550		<1%	102	$18K
86160		<1%	3,684	$18K
H0001	Alcohol and/or drug assessment	<1%	100	$17K
82043		<1%	7,606	$17K
86704		<1%	4,266	$17K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	1,613	$17K
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	<1%	14	$17K
77061		<1%	466	$17K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	581	$16K
11721		<1%	649	$16K
83002		<1%	1,666	$16K
84484		<1%	18,374	$16K
92134		<1%	255	$16K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	261	$16K
81003		<1%	11,680	$15K
76870		<1%	406	$15K
83735		<1%	10,562	$14K
82962		<1%	10,648	$14K
90723		<1%	1,360	$14K
90661		<1%	604	$14K
71045	Radiologic examination, chest; single view	<1%	4,706	$14K
84550		<1%	8,201	$14K
82977		<1%	7,123	$14K
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials	<1%	1,007	$14K
72110		<1%	557	$14K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	231	$14K
83690		<1%	13,204	$14K
99381		<1%	131	$14K
82024		<1%	402	$14K
A9577	Injection, gadobenate dimeglumine (multihance), per ml	<1%	1,160	$14K
19081		<1%	13	$14K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	147	$14K
58100		<1%	39	$13K
90680		<1%	1,135	$13K
84146		<1%	1,219	$13K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	6,185	$13K
95012		<1%	1,214	$13K
72170		<1%	915	$13K
95885		<1%	129	$13K
83516		<1%	2,761	$13K
51729		<1%	29	$13K
96377		<1%	645	$13K
84100		<1%	8,830	$12K
87480		<1%	1,776	$12K
96411		<1%	172	$12K
88300		<1%	904	$12K
97802		<1%	177	$12K
87510		<1%	1,771	$12K
82378		<1%	1,433	$12K
C1874	Stent, coated/covered, with delivery system	<1%	14	$12K
87660		<1%	1,777	$12K
86360		<1%	347	$12K
93922		<1%	295	$12K
99441		<1%	322	$12K
A4648	Tissue marker, implantable, any type, each	<1%	872	$12K
90674		<1%	622	$12K
59841		<1%	14	$11K
72131		<1%	130	$11K
99417	Prolong home eval add 15m	<1%	742	$11K
82550		<1%	6,357	$11K
84445		<1%	277	$11K
73080		<1%	696	$11K
86376		<1%	1,450	$11K
73560		<1%	1,180	$11K
84702		<1%	4,774	$11K
76882		<1%	232	$11K
G0383	Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	<1%	66	$11K
83615		<1%	5,137	$10K
85651		<1%	11,670	$10K
84480		<1%	2,745	$10K
29580		<1%	56	$10K
86334		<1%	1,227	$10K
86431		<1%	4,805	$10K
1036F		<1%	36,705	$10K
29125		<1%	71	$10K
99397		<1%	126	$10K
29540		<1%	64	$10K
86300		<1%	920	$10K
70498		<1%	323	$9K
82533		<1%	1,115	$9K
90846	Family psychotherapy without the patient present, 50 minutes	<1%	70	$9K
86235		<1%	2,784	$9K
19281		<1%	13	$9K
H2010	Comprehensive medication services, per 15 minutes	<1%	153	$9K
0003A		<1%	232	$9K
90633		<1%	1,195	$9K
90472	Immunization administration, each additional vaccine (list separately)	<1%	831	$9K
93308		<1%	55	$9K
81025		<1%	3,873	$9K
92015	Determination of refractive state	<1%	655	$9K
92610		<1%	103	$9K
H0050	Alcohol and/or drug services, brief intervention, per 15 minutes	<1%	177	$9K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	20	$8K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	3,079	$8K
72050		<1%	277	$8K
74018		<1%	732	$8K
83520		<1%	1,144	$8K
90739		<1%	115	$8K
86147		<1%	447	$8K
90694		<1%	629	$8K
86800		<1%	1,215	$7K
82785		<1%	1,243	$7K
72040		<1%	404	$7K
95249		<1%	217	$7K
90480		<1%	322	$7K
64616		<1%	12	$7K
86592		<1%	4,835	$7K
82172		<1%	942	$7K
81374		<1%	109	$7K
86141		<1%	1,388	$7K
87040		<1%	4,056	$7K
82105		<1%	2,096	$7K
90662		<1%	537	$7K
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	175	$7K
0071A		<1%	166	$7K
90620		<1%	561	$7K
51797		<1%	29	$6K
36416		<1%	469	$6K
92558		<1%	195	$6K
87070		<1%	2,279	$6K
73590		<1%	847	$6K
84156		<1%	4,003	$6K
0072A		<1%	157	$6K
87186		<1%	3,057	$6K
83010		<1%	1,131	$6K
76942		<1%	53	$6K
96368		<1%	387	$6K
73523		<1%	262	$6K
82570		<1%	2,829	$6K
95912		<1%	50	$6K
86200		<1%	1,053	$6K
83883		<1%	1,131	$6K
99493		<1%	82	$6K
90882		<1%	322	$6K
73140		<1%	581	$6K
82652		<1%	330	$5K
H0038	Self-help/peer services, per 15 minutes	<1%	222	$5K
84165		<1%	1,486	$5K
36430		<1%	15	$5K
51600		<1%	16	$5K
99383		<1%	37	$5K
90707		<1%	325	$5K
93226		<1%	74	$5K
57454		<1%	12	$5K
88313		<1%	363	$5K
51702		<1%	27	$4K
99401		<1%	53	$4K
J0690	Injection, cefazolin sodium, 500 mg	<1%	4,950	$4K
82627		<1%	320	$4K
92504		<1%	513	$4K
86039		<1%	1,394	$4K
46601		<1%	13	$4K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	232	$4K
86225		<1%	1,466	$4K
C1753	Catheter, intravascular ultrasound	<1%	25	$3K
82565		<1%	1,477	$3K
86038		<1%	1,163	$3K
88177		<1%	73	$3K
84432		<1%	295	$3K
85378		<1%	3,191	$3K
90656		<1%	346	$3K
84481		<1%	769	$3K
82746		<1%	642	$3K
Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	<1%	1,991	$3K
86593		<1%	2,599	$3K
80164		<1%	598	$3K
92526		<1%	21	$3K
71100		<1%	284	$3K
73700		<1%	16	$3K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	67	$3K
G0010	Administration of hepatitis b vaccine	<1%	182	$3K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	1,568	$3K
86762		<1%	422	$3K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	90	$3K
74455		<1%	24	$3K
T1013	Sign language or oral interpretive services, per 15 minutes	<1%	148	$3K
95250		<1%	16	$3K
73090		<1%	482	$3K
86765		<1%	433	$3K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,100	$2K
99358	Prolong nursin fac eval 15m	<1%	27	$2K
88311		<1%	382	$2K
83521		<1%	688	$2K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	14	$2K
77417		<1%	51	$2K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	8,948	$2K
92020		<1%	43	$2K
82247		<1%	1,109	$2K
86682		<1%	1,014	$2K
90746		<1%	66	$2K
90716		<1%	197	$2K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	218	$2K
86618		<1%	261	$2K
T1023	Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter	<1%	37	$2K
83921		<1%	259	$2K
97010		<1%	148	$2K
86256		<1%	218	$2K
93926		<1%	25	$2K
82248		<1%	1,285	$2K
84460		<1%	1,050	$2K
93270		<1%	29	$2K
82947		<1%	4,656	$2K
87075		<1%	654	$2K
72114		<1%	65	$2K
90710		<1%	266	$2K
87205		<1%	1,671	$2K
J3370	Injection, vancomycin hcl, 500 mg	<1%	1,070	$2K
81479	Unlisted molecular pathology procedure	<1%	35	$2K
99384		<1%	12	$2K
83090		<1%	196	$2K
90700		<1%	182	$2K
86335		<1%	78	$2K
J8540	Dexamethasone, oral, 0.25 mg	<1%	938	$2K
83550		<1%	600	$2K
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	661	$1K
83695		<1%	189	$1K
93280		<1%	82	$1K
S0028	Injection, famotidine, 20 mg	<1%	3,594	$1K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	4,396	$1K
84681		<1%	151	$1K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	8,717	$1K
90653		<1%	158	$1K
90696		<1%	184	$1K
73600		<1%	163	$1K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	527	$1K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	13,662	$1K
81002		<1%	1,160	$1K
51784		<1%	31	$1K
82107		<1%	37	$1K
99496		<1%	24	$1K
83930		<1%	706	$1K
73070		<1%	338	$1K
84703		<1%	3,549	$1K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	3,659	$1K
74160		<1%	12	$1K
96523		<1%	42	$1K
S0020	Injection, bupivicaine hydrochloride, 30 ml	<1%	1,977	$1K
A9581	Injection, gadoxetate disodium, 1 ml	<1%	15	$1K
73620		<1%	255	$1K
99153	Mod sedat endo service >5yrs	<1%	620	$1K
J1644	Injection, heparin sodium, per 1000 units	<1%	2,935	$1K
97804		<1%	39	$1K
87430		<1%	934	$1K
84300		<1%	526	$1K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	25	$980.51
80178		<1%	269	$966.91
99152		<1%	771	$962.82
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	29	$950.07
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	7,035	$945.29
84145		<1%	228	$928.28
92133		<1%	12	$922.98
84270		<1%	58	$911.62
S0077	Injection, clindamycin phosphate, 300 mg	<1%	220	$899.29
90698		<1%	146	$876.79
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	305	$874.21
A9699	Radiopharmaceutical, therapeutic, not otherwise classified	<1%	37	$862.56
J1170	Injection, hydromorphone, up to 4 mg	<1%	1,149	$861.44
84425		<1%	132	$830.74
J1815	Injection, insulin, per 5 units	<1%	829	$803.88
82088		<1%	27	$800.17
90714		<1%	40	$796.94
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	3,010	$786.15
84402		<1%	50	$785.67
86606		<1%	195	$781.13
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	11,402	$769.89
83993		<1%	143	$733.19
86304		<1%	77	$723.99
83540		<1%	296	$719.98
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	211	$700.00
85612		<1%	200	$673.90
84436		<1%	248	$648.68
86735		<1%	156	$643.77
C1781	Mesh (implantable)	<1%	26	$619.34
80346		<1%	25	$617.69
S0109	Methadone, oral, 5 mg	<1%	59	$614.95
J9171	Injection, docetaxel, 1 mg	<1%	13	$607.76
70220		<1%	32	$593.11
93793		<1%	95	$590.32
C1819	Surgical tissue localization and excision device (implantable)	<1%	43	$570.24
72070		<1%	61	$536.09
0042T		<1%	12	$522.87
J2270	Injection, morphine sulfate, up to 10 mg	<1%	2,448	$503.45
88360		<1%	16	$503.28
90744		<1%	86	$499.80
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	516	$493.06
G0447	Face-to-face behavioral counseling for obesity, 15 minutes	<1%	13	$483.04
J3475	Injection, magnesium sulfate, per 500 mg	<1%	864	$462.27
87338		<1%	97	$448.92
86580		<1%	29	$447.29
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	106	$447.10
74430		<1%	13	$439.02
4004F		<1%	8,453	$436.63
80069		<1%	68	$385.39
73503		<1%	17	$380.03
87109		<1%	94	$375.09
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	12	$372.43
86709		<1%	120	$367.21
83498		<1%	39	$351.40
86705		<1%	132	$346.88
73060		<1%	100	$340.20
82390		<1%	94	$336.98
90681		<1%	51	$323.44
84144		<1%	24	$309.88
82040		<1%	575	$306.71
82157		<1%	31	$292.80
91308		<1%	86	$275.28
36591		<1%	13	$271.49
J3480	Injection, potassium chloride, per 2 meq	<1%	334	$271.46
82330		<1%	95	$259.28
J1630	Injection, haloperidol, up to 5 mg	<1%	1,950	$255.43
C2617	Stent, non-coronary, temporary, without delivery system	<1%	64	$251.57
C1758	Catheter, ureteral	<1%	100	$241.24
86787		<1%	54	$230.73
86316		<1%	28	$226.85
87116		<1%	43	$226.80
82010		<1%	212	$223.85
84154		<1%	31	$218.84
G2077	Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code	<1%	96	$212.64
84105		<1%	73	$209.61
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	1,107	$206.27
73522		<1%	13	$200.63
87101		<1%	67	$199.85
88302		<1%	13	$189.48
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	3,483	$186.77
83605		<1%	225	$186.18
87077		<1%	76	$185.86
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	866	$178.53
86301		<1%	40	$177.45
J1650	Injection, enoxaparin sodium, 10 mg	<1%	255	$173.34
86328		<1%	18	$172.01
81381		<1%	13	$169.90
77072		<1%	14	$163.96
Q9958	High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml	<1%	28	$156.39
J2060	Injection, lorazepam, 2 mg	<1%	1,281	$154.84
84133		<1%	75	$144.41
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	342	$139.74
82175		<1%	62	$132.79
82397		<1%	14	$125.67
82436		<1%	60	$121.21
86701		<1%	12	$118.90
85007		<1%	155	$116.29
86708		<1%	14	$111.10
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	<1%	2,325	$96.93
73100		<1%	14	$95.90
82610		<1%	15	$88.46
J1580	Injection, garamycin, gentamicin, up to 80 mg	<1%	125	$85.76
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	3,476	$82.11
84132		<1%	80	$81.94
86162		<1%	15	$81.32
82955		<1%	13	$79.70
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	<1%	2,207	$77.10
74019		<1%	14	$73.04
OP250		<1%	66	$69.60
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	2,057	$68.75
85045		<1%	45	$67.59
73552		<1%	13	$62.63
82365		<1%	37	$62.19
85384		<1%	78	$59.60
90611		<1%	109	$55.99
86255		<1%	13	$52.00
91312		<1%	513	$51.10
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	<1%	67	$48.00
83935		<1%	14	$47.50
J1940	Injection, furosemide, up to 20 mg	<1%	164	$43.63
80177		<1%	15	$42.73
82140		<1%	15	$37.12
82150		<1%	14	$30.18
91307		<1%	314	$28.74
85347		<1%	86	$24.34
J7120	Ringers lactate infusion, up to 1000 cc	<1%	43	$22.69
84520		<1%	14	$22.39
84075		<1%	76	$20.61
J7050	Infusion, normal saline solution, 250 cc	<1%	236	$19.83
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	<1%	2,551	$17.84
G9902	Patient screened for tobacco use and identified as a tobacco user	<1%	7,972	$17.01
82270		<1%	55	$15.93
91300		<1%	4,140	$14.15
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	<1%	56	$13.14
84155		<1%	54	$12.91
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	124	$12.80
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	93	$10.36
J0692	Injection, cefepime hydrochloride, 500 mg	<1%	14	$8.89
J2550	Injection, promethazine hcl, up to 50 mg	<1%	163	$7.60
J7644	Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram	<1%	557	$7.48
84450		<1%	56	$6.78
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	68	$6.17
J1598	Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg	<1%	54	$5.82
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	<1%	103	$5.18
J3411	Injection, thiamine hcl, 100 mg	<1%	33	$3.53
87449		<1%	15	$3.30
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	<1%	39	$0.46
G9687	Hospice services provided to patient any time during the measurement period	<1%	92	$0.23
3077F		<1%	247	$0.21
3079F		<1%	308	$0.18
3078F		<1%	328	$0.18
3074F		<1%	298	$0.13
3080F		<1%	141	$0.13
G9903	Patient screened for tobacco use and identified as a tobacco non-user	<1%	15	$0.13
3075F		<1%	212	$0.12
1123F		<1%	126	$0.01
83050		0%	84	$0.00
G2074	Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	0%	39	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	71	$0.00
3044F		0%	13	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	13	$0.00
99080		0%	3,041	$0.00
J1953	Injection, levetiracetam, 10 mg	0%	28	$0.00
99499		0%	1,527	$0.00
J2210	Injection, methylergonovine maleate, up to 0.2 mg	0%	29	$0.00
82375		0%	84	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPASTIER, MICHAEL (SR VICE PRESIDENT)